^
Association details:
| Biomarker: | CD19 positive |
|---|---|
| Cancer: | Mantle Cell Lymphoma |
| Drug Class: | T-lymphocyte cell therapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1153 - IL-4 depletion leads to the improvement of CART cell therapy
Published date:
03/15/2023
Excerpt:
Using a CD19+ JeKo-1 xenograft mouse model, we compared the combination treatment of CART19 cells and an IL-4 neutralizing monoclonal antibody (10 mg/Kg, clone # MP4-25D2) to CART19 cells and an IgG control. IL-4 neutralization in combination with CART19 cells resulted in reduced tumor burden (p = 4.6E-2), increased CART cell proliferation (p = 8E-3), and prolonged overall survival (p= 5E-2).
